Last reviewed · How we verify

ABO-101 — Competitive Intelligence Brief

ABO-101 (ABO-101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy. Area: Hematology/Oncology.

phase 2 Gene therapy FANCC gene Hematology/Oncology Biologic Live · refreshed every 30 min

Target snapshot

ABO-101 (ABO-101) — Abeona Therapeutics, Inc. ABO-101 is a gene therapy that delivers a functional copy of the FANCC gene to correct Fanconi anemia complementation group C deficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABO-101 TARGET ABO-101 Abeona Therapeutics, Inc phase 2 Gene therapy FANCC gene
chemotherapy plus p53 chemotherapy plus p53 Shenzhen SiBiono GeneTech Co.,Ltd marketed Combination chemotherapy with p53 gene therapy p53 tumor suppressor protein
Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi Novartis Gene Therapies marketed Gene therapy SMN1 gene
p53 gene with surgery p53 gene with surgery Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy (p53 tumor suppressor) p53 (tumor protein p53)
Onasemnogene Abeparvovec-brve Onasemnogene Abeparvovec-brve Novartis Pharmaceuticals marketed Gene Therapy SMN1 gene
p53 gene therapy p53 gene therapy Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy p53 (tumor suppressor protein)
p53 with chemotherapy p53 with chemotherapy Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; recombinant adenovirus vector p53 (tumor suppressor protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy class)

  1. Spark Therapeutics, Inc. · 4 drugs in this class
  2. MeiraGTx UK II Ltd · 3 drugs in this class
  3. Novartis Gene Therapies · 2 drugs in this class
  4. Kolon TissueGene, Inc. · 2 drugs in this class
  5. Krystal Biotech, Inc. · 2 drugs in this class
  6. Abeona Therapeutics, Inc · 2 drugs in this class
  7. Larimar Therapeutics, Inc. · 1 drug in this class
  8. 4D Molecular Therapeutics · 1 drug in this class
  9. Medeor Therapeutics, Inc. · 1 drug in this class
  10. MeiraGTx, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABO-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/abo-101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: